Bouhnik J, Galen F X, Menard J, Corvol P, Seyer R, Fehrentz J A, Nguyen D L, Fulcrand P, Castro B
J Biol Chem. 1987 Feb 25;262(6):2913-8.
Polyclonal and monoclonal antibodies were raised against pure human renin, but nothing was known about the regions against which they were directed. Using a three-dimensional model of mouse submandibular renin, we selected seven peptide sequences as belonging to potential epitopes. The main criteria for their choice were the location of the peptide sequences near the catalytic region and on the surface of the renin molecule and their hydrophilicity. After transposition of the regions to the 340-amino acid sequence of human renin, the seven peptides (corresponding to amino acids 50-60, 63-71, 81-90, 118-126, 162-169, 247-255, and 287-295) were synthesized, coupled to bovine serum albumin, and injected into rabbits. Five of these peptides elicited antibodies, and 50-68% binding of the corresponding iodinated peptide was obtained with a 1:25 dilution of antiserum. The antisera titers ranged from 1:5,000 to 1:100,000 when tested by enzyme-linked immunosorbent assay. The same antisera bound 15-65% of labeled pure human renin at a final dilution of 1:2.5, the highest percentage being obtained with peptide 81-90 antiserum. At a 1:5 dilution, the five antisera inhibited renin activity by 23-68% in human plasma with a high renin activity (40 ng of angiotensin I/h/ml). At a final dilution of 1:50, peptide 81-90 antiserum was still capable of producing 25% inhibition. Purified IgG (0.6 mg) from this antiserum inhibited pure human renin activity by up to about 40%, as measured by its reaction with pure synthetic human tetradecapeptide substrate. Antigenic peptides that mimic a part of the human renin sequence, especially peptide 81-90 representing the "flap" covering the cleft between the two renin lobes, constitute promising tools for the development of a synthetic antirenin vaccine.
人们制备了针对纯人肾素的多克隆抗体和单克隆抗体,但对于这些抗体所针对的区域却一无所知。利用小鼠下颌下腺肾素的三维模型,我们选择了七个肽序列,认为它们属于潜在的抗原决定簇。选择这些肽序列的主要标准是其在催化区域附近以及肾素分子表面的位置,以及它们的亲水性。将这些区域转换到人类肾素的340个氨基酸序列后,合成了七个肽(对应于氨基酸50 - 60、63 - 71、81 - 90、118 - 126、162 - 169、247 - 255和287 - 295),将其与牛血清白蛋白偶联,然后注射到兔子体内。其中五个肽引发了抗体,用1:25稀释的抗血清可获得相应碘化肽50 - 68%的结合率。通过酶联免疫吸附测定法检测时,抗血清滴度范围为1:5,000至1:100,000。相同的抗血清在1:2.5的最终稀释度下可结合15 - 65%的标记纯人肾素,肽81 - 90抗血清获得的百分比最高。在1:5的稀释度下,这五种抗血清在高肾素活性(40 ng血管紧张素I/小时/毫升)的人血浆中可抑制肾素活性23 - 68%。在1:50的最终稀释度下,肽81 - 90抗血清仍能产生25%的抑制作用。从该抗血清中纯化的IgG(0.6毫克)通过与纯合成人十四肽底物反应测定,可抑制纯人肾素活性高达约40%。模拟人肾素序列一部分的抗原肽,尤其是代表覆盖两个肾素叶之间裂隙的“瓣”的肽81 - 90,构成了开发合成抗肾素疫苗的有前景的工具。